Aspirin Thrombophlebitis

Aspirin Thrombophlebitis Aspirin Thrombophlebitis Celebrex - FDA prescribing information, side effects and uses

Aspirin Thrombophlebitis

Jul 06, Author: The mainstay of medical therapy has been anticoagulation since the introduction of heparin in the s, Aspirin Thrombophlebitis. More recently, mechanical Aspirin Thrombophlebitis has become increasingly used as endovascular therapies have increased. Absolute contraindications to anticoagulation treatment include intracranial bleeding, severe active bleeding, recent brain, eye, or spinal cord surgery, pregnancy, and malignant hypertension.

Relative contraindications include recent major surgery, recent cerebrovascular accident, and severe thrombocytopenia, Aspirin Thrombophlebitis. Systemic IV thrombolysis once improved the Aspirin Thrombophlebitis of thrombosed vein recanalization; however, it is no longer recommended because of an elevated incidence of bleeding complications, slightly increased risk of death, and insignificant improvement in Aspirin Thrombophlebitis. Thrombolytic therapy is recommended systemic preferred over catheter directed in hypotensive individuals with an acute PE.

The bleeding risk of systemic thrombolysis is similar to that of catheter-directed thrombolysis, and the risk of PTS may further decrease risk. However, whether catheter-directed thrombolysis is preferred to anticoagulation has not been examined. The addition of percutaneous mechanical thrombectomy to the interventional options may facilitate decision-making, because recanalization may be achieved faster than before and with a decreased dose of lytic; therefore, the bleeding risk may be decreased.

Anticoagulant Aspirin Thrombophlebitis is recommended for months depending on site of thrombosis and on the ongoing presence of risk factors, Aspirin Thrombophlebitis. If DVT recurs, if a chronic hypercoagulability is identified, Aspirin Thrombophlebitis, or if PE is life threatening, Aspirin Thrombophlebitis, lifetime anticoagulation therapy may be recommended.

Most patients with confirmed proximal vein DVT Aspirin Thrombophlebitis be safely treated on an outpatient basis, Aspirin Thrombophlebitis. Exclusion criteria for outpatient management are as follows:. For admitted patients treated with UFH, the activated partial thromboplastin time aPTT or heparin activity level must be monitored every 6 hours while the patient is taking intravenous IV heparin until the dose is stabilized in the therapeutic range.

Platelets should be monitored. Heparin or LMWH should be discontinued Salben in den Apotheken von Krampfadern the platelet count falls below 75, Fondaparinux is not associated with hepatin-induced thrombocytopenia HIT, Aspirin Thrombophlebitis.

Long-term anticoagulation is necessary to prevent the high frequency of recurrent Aspirin Thrombophlebitis thrombosis or thromboembolic events.

Anticoagulation does have problems. Although it inhibits propagation, Aspirin Thrombophlebitis, it does not remove the thrombus, and a variable risk of clinically significant bleeding is observed. First-line therapy for non-high risk venous thromboembolism VTE or pulmonary embolism PE consists of Aspirin Thrombophlebitis oral anticoagulants dabigatran, rivaroxaban, apixaban, or edoxaban over vitamin K antagonists VKAs.

Inferior vena cava filters are not recommended in patients with acute VTE on anticoagulant therapy. Barring contraindications to aspirin therapy, aspirin is recommended to prevent recurrent VTE in patients with an unprovoked proximal DVT or PE following anticoagulation cessation. Park and Byun indicate that possibilities for advances in anticoagulant delivery systems include expansion of new oral agents and their antidotes, reducing the size of heparins, developing oral or topical heparins, Aspirin Thrombophlebitis, and modifying physical or chemical formulations, Aspirin Thrombophlebitis.

Aspirin Thrombophlebitis products used in the treatment of deep venous thrombosis DVT include unfractionated heparin and low molecular weight heparin LMWH The efficacy and safety of low-molecular-weight heparin LMWH for the initial treatment of DVT have been well established in several trials.

Traditionally, heparin has been used only for admitted patients with DVT. Regular unfractionated heparin was the standard of care until the introduction of LMWH products.

Heparin prevents extension of the thrombus and has been shown to significantly Aspirin Thrombophlebitis but not eliminate the incidence of fatal and nonfatal pulmonary embolism and recurrent thrombosis. Heparin is a heterogeneous mixture of polysaccharide fragments with varying molecular weights but with similar biological activity. The low-molecular-weight fragments exert their anticoagulant effect by inhibiting the activity of activated factor X, Aspirin Thrombophlebitis.

The hemorrhagic complications attributed to heparin are thought to arise from the larger higher-molecular-weight fragments. Fondaparinux, a direct selective inhibitor of factor Xa, overcomes many of the aforementioned disadvantages of low-molecular-weight heparins LMWHs.

Pharmacokinetic studies of fondaparinux reveal that only a single-daily subcutaneous dose is required. Furthermore, a single dose of 7. Daily doses of 5 mg or 10 mg are appropriate for patients who weigh less or more than that weight range.

Heparin-induced thrombocytopenia HIT has not been reported. Therapeutic monitoring of laboratory parameters such as the prothrombin time or activated partial thromboplastin time aPTT is also not required.

In some regions, Aspirin Thrombophlebitis cost of therapy with fondaparinux is less than enoxaparin when it is being used to bridge therapy to a Aspirin Thrombophlebitis K antagonist VKA. The combination of two factor Xa inhibitors may be an effective treatment strategy for acute venous thromboembolism VTE. Both D-dimer levels and quantitative ultrasound Aspirin Thrombophlebitis QUT scores were improved with the use of fondaparinux, and further reductions were achieved using Aspirin Thrombophlebitis. Buller and his coauthors on behalf of the Matisse Investigators conducted a randomized, double-blind, international study of fondaparinux versus enoxaparin on 2, patients with objectively confirmed acute deep venous thrombosis DVT and found the two agents to be comparable in safety and efficacy.

Fondaparinux was administered as a single 7. Anticoagulation with a VKA was continued for 3 months. Efficacy was measured by the rate of recurrent VTE in the 3-month follow-up period after enrollment. Safety was assessed by the incidence of major bleeding and mortality over the same interval. The recurrence rate showed a nonsignificant trend in favor of fondaparinux 3.

Major bleeding rates were essentially identical, and mortality rates were also comparable, Aspirin Thrombophlebitis. In general, the safety and efficacy of fondaparinux were independent of body weight.

However, Aspirin Thrombophlebitis, patients Aspirin Thrombophlebitis mild renal insufficiency and a low creatinine clearance had the same risk of bleeding in both the LMWH and fondaparinux groups. Overall, the authors concluded that once-daily fondaparinux was as effective and as safe as twice-daily, weight-adjusted enoxaparin. Only one fixed-dosage regimen for fondaparinux is required for patients Aspirin Thrombophlebitis weigh between 50 kg and kg, and only one subcutaneous dose per day is required, Aspirin Thrombophlebitis.

This greatly simplifies the treatment of DVT and facilitates outpatient therapy. In the original study, Aspirin Thrombophlebitis, about one third of the patients were treated partially or entirely as outpatients without any increased risk when compared with those treated as inpatients.

In the event of a major bleed, protamine sulfate partially reverses the anticoagulant effect Aspirin Thrombophlebitis enoxaparin. However, no specific antidote to fondaparinux is available. Participants were randomly assigned to receive rivaroxaban, a combination of enoxaparin and a VKA eg, warfarinor a placebo. Study endpoints were Aspirin Thrombophlebitis to measure the number of patients who experienced recurrent symptoms of DVT, PE, or death after receiving treatment.

Dabigatran Pradaxa inhibits free and clot-bound thrombin wie die meisten Varizen bestimmen thrombin-induced platelet aggregation.

This agent was FDA approved in to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In Aprilit was approved for the treatment of DVT and PE in patients who have been treated with a parenteral anticoagulant for days, Aspirin Thrombophlebitis.

Additionally, it was approved to reduce the risk of DVT and PE recurrence in patients who have been previously treated. Approval was based on results from 4 global phase III trials that showed dabigatran was noninferior to warfarin and had a lower risk of major or clinically relevant bleeding compared with warfarin.

Results showed dabigatran was noninferior to warfarin in reducing DVT and PE after a median of days of treatment with a lower risk of bleeding compared with warfarin, Aspirin Thrombophlebitis.

Results from this trial showed dabigatran was noninferior to warfarin in the extended treatment of VTE and carried a lower risk of major or clinically relevant Aspirin Thrombophlebitis than warfarin. Among patients with PE, Aspirin Thrombophlebitis, had right ventricular dysfunction, as assessed by measurement of N-terminal pro-brain natriuretic peptide NT-proBNP levels. The investigators concluded that edoxaban was not only noninferior to high-quality standard warfarin therapy but also caused significantly less bleeding in a broad spectrum of patients with VTE, including those with severe PE.

Approval of betrixaban was based on data from the phase 3 APEX studies. Patients in the enoxaparin group received 40 mg subcutaneously once daily for days and took an oral placebo once daily for days. Efficacy was measured in 7, patients using a composite outcome score composed of the occurrence Aspirin Thrombophlebitis asymptomatic or symptomatic proximal DVT, Aspirin Thrombophlebitis, nonfatal PE, stroke, or VTE-related death.

For the first episode of deep venous thrombosis DVTpatients should be treated for months. Recurrent episodes should be treated for at least 1 year. Prandoni et al found that the use of ultrasonography to determine the duration of anticoagulation can reduce recurrences of venous thromboembolism after a first episode of acute proximal DVT.

Recurrent venous thromboembolism developed in Patients with cancer have a particularly higher rate of DVT recurrence than noncancer patients. Long-term therapy for DVT is strongly recommended. Studies have shown a lower rate Aspirin Thrombophlebitis venous thromboembolism VTE recurrence without increasing the risk of bleeding with low-molecular-weight heparin LMWH therapy. Reports also describe that the LMWH compounds may decrease the all-cause mortality rate, Aspirin Thrombophlebitis.

Indefinite therapy is recommended for patients with recurrent episodes of venous thrombosis regardless of the cause. Long-term therapy with LMWH has been shown to be as effective as warfarin in the treatment of venous thrombosis, except in those patients with a concurrent malignancy.

In this subgroup, LMWH was shown to be more effective than oral therapy. Hemorrhagic complications are the most common adverse effects of anticoagulant therapy. Patients who require yearlong or indefinite anticoagulation because of chronic risk factors have double the risk of hemorrhage.

Significant bleeding ie, hematemesis, hematuria, Aspirin Thrombophlebitis, GI hemorrhage should be thoroughly investigated because anticoagulant therapy may unmask a preexisting disease eg, Aspirin Thrombophlebitis, cancer, peptic ulcer disease, arteriovenous malformation.

The treatment of hemorrhage while taking heparin depends on the severity of the bleeding and the extent to which the Aspirin Thrombophlebitis partial thromboplastin time aPTT is elevated above the therapeutic range. Patients who hemorrhage while receiving heparin are best treated by discontinuing the drug.

The half-life is relatively short, and the aPTT usually returns to the reference range within a few hours. Treatment with fresh frozen plasma or platelet infusions is ineffective. For severe hemorrhage, Aspirin Thrombophlebitis, such as intracranial or massive gastrointestinal bleeding, heparin may be neutralized by protamine at a dose of 1 mg for every units. Protamine should be administered at the same time Aspirin Thrombophlebitis the infusion is stopped. The treatment of major hemorrhage associated with low-molecular-weight heparin LMWH is similar to heparin.

However, the half-life of these agents is longer h. As with heparin, fresh frozen plasma or platelet transfusions are ineffective, Aspirin Thrombophlebitis. The risk of bleeding on warfarin is not linearly related to the elevation of the international normalized ratio INR.

The risk is conditioned by other factors, including poor follow-up, Aspirin Thrombophlebitis, drug interactions, age, Aspirin Thrombophlebitis, and preexisting disorders that predispose to bleeding.

Patients who hemorrhage while receiving oral warfarin are treated by withholding the drug and administering vitamin K. Severe life-threatening hemorrhage is managed with fresh frozen plasma in addition to vitamin K.

Recombinant factor VIIa is another option especially for central Aspirin Thrombophlebitis system hemorrhage. The qualities desired in the ideal anticoagulant are ease of administration, efficacy and safety Aspirin Thrombophlebitis minimal complications or adverse effectsrapid onset, a therapeutic half-life, and minimal or no monitoring.

Aspirin Thrombophlebitis

The chemical name is - 4-chlorobenzoyl methoxymethyl-1 H indole- 3- Aspirin Thrombophlebitis acid, Aspirin Thrombophlebitis. The molecular weight is Indomethacin is a white to yellow crystalline powder.

It is practically insoluble in water and sparingly soluble in alcohol. Indomethacin has a pKa of 4. The suspension has a pH of 4. Get emergency medical help if you have any of these signs of an allergic reaction: Stop taking indomethacin and seek medical attention or call your doctor at once if you have any of these serious side effects:.

After observing the response to initial therapy with indomethacin, the dose and frequency should be adjusted to suit an individual patient's needs. Adverse reactions generally appear to correlate with the dose of indomethacin. Therefore, every effort should be made to determine Cholesterin aus Varizen lowest effective dosage for the individual patient.

If this is well tolerated, increase the daily dosage by 25 mg 5 mL or by 50 mg 10 mLif required by continuing symptoms, at weekly intervals until a satisfactory response is obtained or until a total daily dose of mg 30 - 40 mL is reached. Doses above this amount generally do not increase the effectiveness of the drug. Aspirin Thrombophlebitis total daily dose should not exceed mg 40 mL. In acute flares of chronic rheumatoid arthritisit may be necessary to increase the dosage by 25 mg 5 mL or, if required, by 50 mg 10 mL daily.

If minor adverse effects develop as the dosage is increased, reduce the dosage rapidly to a tolerated dose and observe the patient closely. If severe adverse reactions occur, stop the drug. After the acute phase of the disease is under control, an attempt to reduce the daily dose should be made repeatedly until the patient is receiving the smallest effective dose or the drug is discontinued, Aspirin Thrombophlebitis.

Careful instructions to, and observations of, the individual patient are essential to the prevention of serious, irreversible, including fatal, adverse reactions. The drug should be discontinued after the signs and symptoms of inflammation have been controlled for several days.

The usual course of therapy is days. The dose should then be rapidly reduced to complete cessation of the drug. Definite relief of pain has been reported within 2 to 4 hours. Tenderness and heat usually subside in 24 to 36 hours, Aspirin Thrombophlebitis swelling gradually disappears in 3 to 5 days, Aspirin Thrombophlebitis. It is supplied as follows:. The following adverse reactions are discussed in greater detail Aspirin Thrombophlebitis other sections of the labeling:.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In a double-blind comparative clinical study involving patients with rheumatoid arthritishowever, the incidence of upper gastrointestinal adverse effects with INDOCIN Suppositories or Capsules was comparable.

The incidence of lower gastrointestinal adverse effects was greater in the suppository group, Aspirin Thrombophlebitis. The incidence for group 1 was obtained from 33 Brokkoli mit Krampfadern controlled clinical trials Aspirin Thrombophlebitis in the literature 1, patients. The incidence for group 2 was based on reports in clinical trials, in the literature, and on voluntary reports since marketing, Aspirin Thrombophlebitis.

The probability of a causal relationship exists between INDOCIN and these adverse reactions, some of which have been reported only rarely. Other reactions have been reported but occurred under circumstances where a causal relationship could not be established.

However, in these rarely reported events, Aspirin Thrombophlebitis, the possibility cannot be excluded. Therefore, these observations are being listed to serve as alerting information to physicians:. Although there have been several reports of leukemiaAspirin Thrombophlebitis, the supporting information is weak.

Indomethacin and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of Aspirin Thrombophlebitis and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin Aspirin Thrombophlebitis by platelets plays an important role Aspirin Thrombophlebitis hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may Aspirin Thrombophlebitis the risk of bleeding more than an NSAID alone.

In patients who are elderly, volume-depleted including those on diuretic therapyor have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. When these drugs are administered concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter.

Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics e. It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.

The potential effects of INDOCIN and potassium-sparing diuretics on potassium levels and renal function should be considered when these agents are administered concurrently. Indomethacin and triamterene should not be administered together.

During concomitant use of INDOCIN with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects. The concomitant use of INDOCIN with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance.

In some patients, combined use of indomethacin and diflunisal has been associated with Aspirin Thrombophlebitis gastrointestinal Aspirin Thrombophlebitis. The concomitant use of indomethacin with other NSAIDs or salicylates, especially diflunisal, is not recommended. Concomitant use of INDOCIN and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity see the pemetrexed prescribing information, Aspirin Thrombophlebitis.

NSAIDs with short elimination half-lives e. In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives e. When indomethacin is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.

During the concomitant use of INDOCIN and probenecid, a lower total daily dosage of indomethacin may produce a satisfactory therapeutic effect. When increases in the dose of indomethacin are made, they should be made carefully and in small increments, Aspirin Thrombophlebitis. These facts should be considered when evaluating plasma renin activity in hypertensive patients.

False-negative results in the dexamethasone suppression test DST in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients. Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular CV thrombotic events, including myocardial infarction MI and strokewhich can be fatal.

However, Aspirin Thrombophlebitis, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due Aspirin Thrombophlebitis their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in Wie man Krampfadern Wunden behandeln thrombotic risk has been Aspirin Thrombophlebitis most consistently at higher doses.

To minimize the potential risk for an adverse CV event in NSAID-treated patients, Aspirin Thrombophlebitis, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development Aspirin Thrombophlebitis such events, throughout the entire treatment course, even in the absence of previous CV symptoms.

Patients should be informed about the symptoms of serious CV events and the steps to take if they occur. There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, Aspirin Thrombophlebitis, CV-related death, and allcause mortality beginning in the first week of treatment.

Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up. NSAIDs, including indomethacin, Aspirin Thrombophlebitis, cause serious gastrointestinal GI adverse events including inflammation, Aspirin Thrombophlebitis, bleeding, ulcerationand perforation of the esophagusstomach, Aspirin Thrombophlebitis, small intestineAspirin Thrombophlebitis, or large intestinewhich can be fatal, Aspirin Thrombophlebitis.

These serious adverse events can occur at any time, with or without warning symptoms, Aspirin Thrombophlebitis, in patients treated with NSAIDs. Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of Aspirin Thrombophlebitis corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors SSRIs ; smoking; use of alcohol; older age; and poor general health status.

Most postmarketing reports of fatal GI events occurred in elderly or debilitated patients. In addition, rare, sometimes fatal, cases of severe hepatic injury, including fulminant hepatitisliver necrosisand hepatic failure have been reported, Aspirin Thrombophlebitis. Inform patients of the warning signs and symptoms of hepatotoxicity e. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur e.

The Coxib and traditional NSAID Trialists' Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. Use of indomethacin may blunt the CV effects of several therapeutic agents used to treat these medical conditions e. Avoid the use of INDOCIN in patients with severe heart Aspirin Thrombophlebitis unless the benefits are expected to outweigh the risk of worsening heart failure.

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dosedependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.

Patients at greatest risk of this reaction are those with impaired renal function, Aspirin Thrombophlebitis, dehydration, hypovolemiaheart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly.

Avoid the use of INDOCIN in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. It has been reported that the addition of the potassium -sparing diuretictriamterene, to a maintenance schedule of indomethacin resulted in reversible acute renal failure in two of four healthy volunteers. Increases in serum potassium concentration, including hyperkalemiahave been reported with use of NSAIDs, even in some patients without renal impairment.

In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state. Both Indomethacin and potassium-sparing diuretics may be associated with increased serum potassium levels. The potential effects of indomethacin and potassium-sparing diuretics on potassium levels and renal function should be considered when these agents are administered concurrently. When INDOCIN is used in patients with preexisting asthma without known aspirin sensitivitymonitor patients for changes in the signs and symptoms of asthma, Aspirin Thrombophlebitis.

These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin reactions, and to discontinue the use of INDOCIN at the first appearance of skin rash or any other sign of hypersensitivity. Indomethacin may cause premature closure of the fetal ductus arteriosus. This may be due to occult or gross blood loss, Aspirin Thrombophlebitis, fluid retention, or an incompletely described effect on erythropoiesis.

Co-morbid conditions, such as coagulation disorders, or concomitant use of warfarin, other anticoagulants, antiplatelet agents e. The pharmacological activity of INDOCIN in reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infections. INDOCIN may aggravate depression or other psychiatric disturbances, epilepsyAspirin Thrombophlebitis, and parkinsonismand should be used with considerable caution in patients with these conditions, Aspirin Thrombophlebitis.

Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

Related queries:
- Kuriozin Lösung trophischen Geschwüren
Learn about Indocin (Indomethacin) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications.
- Operation von Krampfadern in den unteren Extremitäten
Deep venous thrombosis (DVT) is a manifestation of venous thromboembolism (VTE). Although most DVT is occult and resolves spontaneously without complication, death.
- Varizen nach der Massage
Get TOA: Definition and Meaning. Check out What does TOA mean? along with list of similar terms on
- weinend für venöse Geschwüre
Learn about Indocin (Indomethacin) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications.
- Krampfadern-Behandlung-Creme
Learn about Indocin (Indomethacin) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications.
- Sitemap